Intra Vaginal Drug Delivery System: an Overview

Total Page:16

File Type:pdf, Size:1020Kb

Intra Vaginal Drug Delivery System: an Overview American Journal of Advanced Drug Delivery www.ajadd.co.uk Review Article Intra Vaginal Drug Delivery System: An Overview Chinmaya Keshari Sahoo* 1, Prakash Kumar Nayak 2, Deepak Kumar Sarangi 3, Tanmaya Keshari Sahoo 4 1Research Scholar, Osmania University College of Technology, Osmania University,Hyderabad, A.P. - 500007 2Norwich clinical Services Pvt. Ltd., Clinical Research co-ordinator cum Pharmacist, Sahakara Nagar, Banglore- 560092 3Omega College of Pharmacy, Edulabad, Ranga Reddy-501301 4Institute of Pharmacy and Technology, Salipur, Cuttack, Odisha-754202 Date of Receipt - 17/04/2013 ABSTRACT Date of Revision- 17/04/2013 Date of Acceptance- 22/04/2013 The human vagina represents a potential, accessible space that offers a valuable route for drug delivery through the use of specifically designed carrier systems for both local and systemic applications. Intra-vaginal drug delivery is particularly appropriate for drugs associated with women's health issues but may also have applications in general drug delivery within the female population. Vagina is one of the best routes for drugs administration like contraceptive steroids, metronidazole, anti-retroviral, etc. An intra-vaginal controlled-release drug delivery system is an effective means for achieving a continuous delivery of therapeutic agents, not only the systemically active drugs, such as contraceptive steroids, but also the locally active drugs, such as metronidazole and other drugs like Zidovudine, Lamivudine, etc. Address for This continuous “infusion” of drugs through the vaginal mucosa can Correspondence prevent the possibility of hepato-gastrointestinal first-pass Osmania University metabolism gastric irritation of drugs and fluctuation of dosing College of Technology, interval. The advantage of intra-vaginal controlled drug Osmania administration over conventional/traditional oral administration is the drug absorbed systemically, because due to the presence of dense University,Hyderabad, network of blood vessels in vaginal wall. A range of drug delivery A.P.-500007 platforms suitable for intra-vaginal administration are hydro-gels, vaginal tablets, pessaries/suppositories, particulate systems, and E-mail: intra-vaginal rings. sahoo.chinmaya83@g mail.com Keywords : Vagina, First pass metabolisim, Intra vaginal drug delivery, pessaries. American Journal of Advanced Drug Delivery www.ajadd.co.uk Sahoo et al______________________________________________________ ISSN-2321-547X INTRODUCTION Vagina is route for administration for Variability in drug absorption related with contraceptives, anti-fungal, and menstrual cycle, menopause and antimicrobials. It is used for the pregnancy, achievement of local or for systemic Influence with sexual intercourse 4. absorption. The vaginal wall is very well Personal hygiene. suited for the absorption of drugs for Some drugs are sensitive at vaginal pH systemic use. As it contains a vast network of blood vessels 1. VAGINAL ANATOMY AND This route offers certain advantages, PHYSIOLOGY WITH RESPECT TO such as avoidance of gut and hepatic first DRUG DELIVERY pass metabolism, reduction in The vagina is a fibro-muscular tube gastrointestinal and hepatic side effects, and approximately 10 cm in length comprised of local targeting of drugs to the reproductive three distinct layers namely; organs. Vaginally administered agents and an outer adventitial layer, formulations are mainly being developed to a middle muscularis layer and provide “dual prophylaxis” for contraception An innermost mucosal layer 5 and protection against microbial infections 2 The vaginal rugae and micro-ridges on including Acquired Immune Deficiency the epithelial cell surface permit the vagina Syndrome(AIDS) and other sexually to expand, allow the placement of vaginal transmitted diseases (STDs). Drug delivery formulations and increase the surface area of technologies that have been used for vaginal the vagina thus enhancing drug absorption 6. drug delivery include the intra-vaginal ring The vagina has remarkable features in (IVR) and Vaginal Site bio-adhesive terms of vaginal secretion, pH, enzyme technology. activity and micro-flora. These factors affect formulation spreading and retention as well Advantages of intra vaginal drug delivery as absorption and drug release in vagina. system Prolonged release, Vaginal Secretions Minimal systemic side effects, The vaginal discharge is a mixture of An increase in bioavailability, multiple secretions that collect in the vagina Use of less total drug than an oral dose, from peritoneal, follicular tubal, uterine, First-pass metabolism can be avoided, Bartholin's and Skene's glands 7. In presence Self medication is possible. of moisture, solid dosage formulations should Contact with digestive fluid is avoided ideally disperse in the vaginal canal and degradation of drug is minimized 3. immediately after insertion to avoid Nausea, vomiting, emesis induced inconvenience to the users. through oral administration is avoided. Quick onset of action. Enzyme Activity The specific enzymatic activity of Disadvantages four different amino peptidases in vaginal Gender specificity, homogenates decreases in the order: sheep > Patient incompliance, guinea pig > rabbit ≥ human ≥ rat 8 . The Only a few drugs are administered by this human genital tract has lower enzymatic route, activity leading to less degradation of protein AJADD1[1][2013]043-055 Sahoo et al______________________________________________________ ISSN-2321-547X and peptide drugs in the vagina than the following factors: gastrointestinal tract 9. Physiological Factors Vaginal pH changes in the thickness of epithelium The pH of the healthy female genital layer, tract is acidic (pH 3.5–4.5) and is maintained cyclic changes, within that range by bacterial conversion of changes in the hormones level, glycogen from exfoliated epithelial cells to volume of vaginal fluid, lactic acid 10 . alteration of vaginal pH and Sexual arousal can potentially affect drug Ideality of intra vaginal drug delivery release from any intravaginal delivery system system and also alter its rate of Component should melt at vaginal absorption. temperature i.e. at 36 °C, For e.g. Intra-vaginal drug delivery device 1. Vaginal absorption of steroids is affected should be non-toxic and non irritating, by the thickness of vaginal epithelium 11 . It should not have any meta-stable form, 2. Vaginal absorption of estrogen shows The preparation should have wetting and high in post menopausal women emulsifying properties. compare to premenopausal women 12 . It should have proper viscosity, so avoid The high volume of vaginal fluid the leakage of preparation from vagina may increase the absorption of poorly water (in case of semisolid dosage form), soluble drugs; however the same condition The preparation should have proper bio- again responsible to remove the drug from adhesive/muco-adhesive properties, so the vaginal cavity and subsequent reduction increase the contact time between the of drug absorption. membrane and Preparation. Further cervical mucus, a glycoprotein gel can possibly be exploited for bioadhesive drug delivery. However at FACTORS AFFECTING ABSORPTION the same time it may serve as a permeability OF DRUGS barrier for different drug candidates 13 . Again changes in the pH of vagina will alter degree The drug transport across vaginal of ionization of weak electrolytic drugs and membrane mainly takes place by three major affect the release profile of pH sensitive ways; drugs 14 . Transcellularly- via concentration dependent diffusion through the cells, Physicochemical Factors Paracellularly- mediated via tight Lipophilicity, junctions and Ionization, Vesicular or receptor mediated transport. Molecular weight, Drug absorption from vaginal delivery Surface charge and system is mainly takes place in two main Chemical nature can influence the vaginal steps: drug absorption. Drug dissolution in vaginal lumen and In consideration to permeability the Membrane penetration. lipophilic steroids like progesterone and The rate and extent of drug absorption estrone having better permeability than the after intra-vaginal administration may vary depending on AJADD1[1][2013]043-055 Sahoo et al______________________________________________________ ISSN-2321-547X hydrophilic one like hydrocortisone and shape of number 7 Copper is released by a testosterone. combination of ionization and chelation from a copper wire wrapped around the Vaginal & Uterine Route for vertical limb. This is effective for up to 40 Sustained/Controlled Release drug m. Delivery Application of prostaglandin containing vaginal rings for induction of labor or Sustained and controlled-release pregnancy termination. Anti-fungals have devices for drug delivery in the vaginal and been important drug candidates for the uterine areas are most often for the delivery treatment of gynecological conditions. of contraceptive steroid hormones. One such The vaginal delivery of azole anti- application is the medicated vaginal ring. gungals as clotrimazole, miconazole, Medicated vaginal rings fabricated from econazole, itraconazole and sertaconazole is silastic 382 medical grade elastomer. These effective in the topical treatment of vaginal are of ‘doughnut-shaped’. Also known as candidiasis. intra-vaginal rings or V-Rings. Vaginal rings provide a means of delivering a drug to the systemic circulation Novel concepts in vaginal drug delivery at a controlled release rate. Several vaginal ring products are currently
Recommended publications
  • Pregnant Body Book
    THETHE COMPLETECOMPLETE ILLUSTRATEDILLUSTRATED GUIDEGUIDE FROMFROM CONCEPTIONCONCEPTION TOTO BIRTHBIRTH THE PREGNANT BODY BOOK THE PREGNANT BODY BOOK DR. SARAH BREWER SHAONI BHATTACHARYA DR. JUSTINE DAVIES DR. SHEENA MEREDITH DR. PENNY PRESTON Editorial consultant DR. PAUL MORAN GENETICS 46 THE MOLECULES OF LIFE 48 HOW DNA WORKS 50 PATTERNS OF INHERITANCE 52 GENETIC PROBLEMS AND 54 INVESTIGATIONS THE SCIENCE OF SEX 56 THE EVOLUTION OF SEX 58 ATTRACTIVENESS 62 HUMAN PREGNANCY 6 DESIRE AND AROUSAL 64 THE EVOLUTION OF PREGNANCY 8 THE ACT OF SEX 66 MEDICAL ADVANCES 10 BIRTH CONTROL 68 IMAGING TECHNIQUES 12 GOING INSIDE 14 CONCEPTION TO BIRTH 70 TRIMESTER 1 72 ANATOMY 24 MONTH 1 74 BODY SYSTEMS 26 WEEKS 1–4 74 THE MALE REPRODUCTIVE SYSTEM 28 MOTHER AND EMBRYO 76 THE PROSTATE GLAND, PENIS, 30 AND TESTES KEY DEVELOPMENTS: MOTHER 78 MALE PUBERTY 31 CONCEPTION 80 HOW SPERM IS MADE 32 FERTILIZATION TO IMPLANTATION 84 THE FEMALE REPRODUCTIVE SYSTEM 34 EMBRYONIC DEVELOPMENT 86 THE OVARIES AND FALLOPIAN TUBES 36 SAFETY IN PREGNANCY 88 THE UTERUS, CERVIX, AND VAGINA 40 DIET AND EXERCISE 90 THE BREASTS 42 MONTH 2 92 FEMALE PUBERTY 43 WEEKS 5–8 92 THE FEMALE REPRODUCTIVE CYCLE 44 MOTHER AND EMBRYO 94 CONTENTS london, new york, melbourne, DESIGNERS Riccie Janus, ILLUSTRATORS munich, and dehli Clare Joyce, Duncan Turner DESIGN ASSISTANT Fiona Macdonald SENIOR EDITOR Peter Frances INDEXER Hilary Bird CREATIVE DIRECTOR Rajeev Doshi SENIOR ART EDITOR Maxine Pedliham SENIOR 3D ARTISTS Rajeev Doshi, Arran Lewis PICTURE RESEARCHERS Myriam Mégharbi, 3D ARTIST Gavin Whelan PROJECT EDITORS Joanna Edwards, Nathan Joyce, Karen VanRoss Lara Maiklem, Nikki Sims ADDITIONAL ILLUSTRATORS PRODUCTION CONTROLLER Erika Pepe Peter Bull Art Studio, Antbits Ltd EDITORS Salima Hirani, Janine McCaffrey, PRODUCTION EDITOR Tony Phipps Miezan van Zyl DVD minimum system requirements MANAGING EDITOR Sarah Larter PC: Windows XP with service pack 2, US EDITOR Jill Hamilton MANAGING ART EDITOR Michelle Baxter Windows Vista, or Windows 7: Intel or AMD processor; soundcard; 24-bit color display; US CONSULTANT Dr.
    [Show full text]
  • Chapter 28 *Lecture Powepoint
    Chapter 28 *Lecture PowePoint The Female Reproductive System *See separate FlexArt PowerPoint slides for all figures and tables preinserted into PowerPoint without notes. Copyright © The McGraw-Hill Companies, Inc. Permission required for reproduction or display. Introduction • The female reproductive system is more complex than the male system because it serves more purposes – Produces and delivers gametes – Provides nutrition and safe harbor for fetal development – Gives birth – Nourishes infant • Female system is more cyclic, and the hormones are secreted in a more complex sequence than the relatively steady secretion in the male 28-2 Sexual Differentiation • The two sexes indistinguishable for first 8 to 10 weeks of development • Female reproductive tract develops from the paramesonephric ducts – Not because of the positive action of any hormone – Because of the absence of testosterone and müllerian-inhibiting factor (MIF) 28-3 Reproductive Anatomy • Expected Learning Outcomes – Describe the structure of the ovary – Trace the female reproductive tract and describe the gross anatomy and histology of each organ – Identify the ligaments that support the female reproductive organs – Describe the blood supply to the female reproductive tract – Identify the external genitalia of the female – Describe the structure of the nonlactating breast 28-4 Sexual Differentiation • Without testosterone: – Causes mesonephric ducts to degenerate – Genital tubercle becomes the glans clitoris – Urogenital folds become the labia minora – Labioscrotal folds
    [Show full text]
  • Persistent Genital Arousal Disorder (PGAD) in Women: Mental Or Body
    Persistent Genital Arousal Disorder (PGAD) in Women: Mental or Body Irwin Goldstein MD Director, Sexual Medicine, Alvarado Hospital, San Diego, California Clinical Professor of Surgery, University of California, San Diego Editor-in-Chief, The Journal of Sexual Medicine Interim Editor-in-Chief, Sexual Medicine Reviews Persistent Genital Arousal Disorder (PGAD) Persistent genital arousal disorder (PGAD) (formerly PSAS) is a rare, unwanted and intrusive sexual dysfunction associated with excessive and unremitting genital arousal and engorgement in the absence of sexual interest PGAD is extremely frustrating and can lead to suicidal ideation and attempts The persistent genital arousal usually does not resolve with orgasm Persistent Genital Arousal Disorder: during PGAD episode Homuncular genital representation Normal clitoris projection PGAD attack Increased Central sexual peripheral arousal reflex pudendal center that is nerve overly excited sensory and under afferent inhibited input Pain and Orgasm Share Common Neurologic Pathways – Lateral Spinothalamic Tract Pain and Orgasm Share Common Neurologic Pathways – Lateral Spinothalamic Tract The spinothalamic tract is a sensory pathway originating in the spinal cord The spinothalamic tract transmits afferent information to the thalamus about pain, temperature, itch and crude touch The types of sensory information transmitted via the spinothalamic tract are described as “affective sensation” - the sensation is accompanied by a compulsion to act. For instance, an itch is accompanied by a need to scratch, and a painful stimulus makes us want to withdraw from the pain Female Sexual Response Cycle Orgasm PGAD ????? = limited resolution of the genital arousal Plateau ………………………… (D) Excitement (B) ABC (C) (A) Adapted from Masters WH, Johnson VE. Human Sexual Inadequacy. Little Brown; 1970.
    [Show full text]
  • Gel-Syn™ Product Information Caution
    GEL-SYN™ PRODUCT INFORMATION CAUTION: Federal law restricts this device to sale by or on the order of a physician (or properly licensed practitioner). CONTENT Each 1 mL of Gel-Syn contains: Sodium Hyaluronate: 8.4 mg Sodium Chloride: 8.5 mg Sodium Phosphate, Dibasic: 0.16 mg Sodium Phosphate, Monobasic: 0.045 mg Water for Injection: q.s. to 1.0 mL DESCRIPTION Gel-Syn is a sterile, buffered solution of highly purified sodium hyaluronate with a molecular weight of approximately 1100 kDa, obtained through fermentation of Streptococci of Lancefield groups A and C and chemically unmodified. INDICATION Gel-Syn is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen). CONTRAINDICATIONS • Do not administer to patients with known hypersensitivity (allergy) to sodium hyaluronate preparations. • Do not inject Gel-Syn into the knees of patients having knee joint infections or skin diseases or infections in the area of the injection site. WARNINGS • Do not concomitantly use disinfectants containing quaternary ammonium salts for skin preparation because sodium hyaluronate can precipitate in their presence. • Inject into the synovial space only. Do not inject by intravascular route. • Do not inject outside the synovial space or into the synovial tissue or capsule. An extra- articular injection of the product can cause local adverse events. PRECAUTIONS General • The safety and effectiveness of Gel-Syn in locations other than the knee, and for conditions other than osteoarthritis, have not been established. • Strict aseptic administration technique must be followed.
    [Show full text]
  • Physical-Chemical Characteristics of Whitening Toothpaste and Evaluation of Its Effects on Enamel Roughness
    Dental materials Physical-chemical characteristics of whitening toothpaste and evaluation of its effects on enamel roughness Sérgio Paulo Hilgenberg(a) Abstract: This in vitro study evaluated the physical-chemical characteris- (a) Shelon Cristina Souza Pinto tics of whitening toothpastes and their effect on bovine enamel after ap- Paulo Vitor Farago(b) Fábio André Santos(a) plication of a bleaching agent (16% carbamide peroxide). Physical-chem- Denise Stadler Wambier(a) ical analysis was made considering mass loss by desiccation, ash content and pH of the toothpastes. Thirty bovine dental enamel fragments were prepared for roughness measurements. The samples were subjected to (a) Department of Dentistry, School of Dentistry, Ponta Grossa State University, bleaching treatments and simulated brushing: G1. Sorriso Dentes Brancos Ponta Grossa, PR, Brazil. (Conventional toothpaste), G2. Close-UP Whitening (Whitening tooth- (b) Department of Pharmacy, School of paste), and G3. Sensodyne Branqueador (Whitening toothpaste). The av- Dentistry, Ponta Grossa State University, erage roughness (Ra) was evaluated prior to the bleaching treatment and Ponta Grossa, PR, Brazil. after brushing. The results revealed differences in the physical-chemical characteristics of the toothpastes (p < 0.0001). The final Ra had higher values (p < 0.05) following the procedures. The mean of the Ra did not show significant differences, considering toothpaste groups and bleach- ing treatment. Interaction (toothpaste and bleaching treatment) showed significant difference
    [Show full text]
  • An Introduction to Fast Dissolving Oral Thin Film Drug Delivery Systems: a Review
    Muthadi Radhika Reddy /J. Pharm. Sci. & Res. Vol. 12(7), 2020, 925-940 An Introduction to Fast Dissolving Oral Thin Film Drug Delivery Systems: A Review Muthadi Radhika Reddy1* 1School of pharmacy, Gurunanak Institute of Technical Campus, Hyderabad, Telangana, India and Department of Pharmacy, Gandhi Institute of Technology and Management University, Vizag, Andhra Pradesh, India INTRODUCTION 2. Useful in situations where rapid onset of action Fast dissolving drug delivery systems were first developed required such as in motion sickness, allergic attack, in the late 1970s as an alternative to conventional dosage coughing or asthma forms. These systems consist of solid dosage forms that 3. Has wide range of applications in pharmaceuticals, Rx disintegrate and dissolve quickly in the oral cavity without Prescriptions and OTC medications for treating pain, the need of water [1]. Fast dissolving drug delivery cough/cold, gastro-esophageal reflux disease,erectile systems include orally disintegrating tablets (ODTs) and dysfunction, sleep disorders, dietary supplements, etc oral thin films (OTFs). The Centre for Drug Evaluation [4] and Research (CDER) defines ODTs as,“a solid dosage 4. No water is required for the administration and hence form containing medicinal substances which disintegrates suitable during travelling rapidly, usually within a matter of seconds, when placed 5. Some drugs are absorbed from the mouth, pharynx upon the tongue” [2]. USFDA defines OTFs as, “a thin, and esophagus as the saliva passes down into the flexible, non-friable polymeric film strip containing one or stomach, enhancing bioavailability of drugs more dispersed active pharmaceutical ingredients which is 6. May offer improved bioavailability for poorly water intended to be placed on the tongue for rapid soluble drugs by offering large surface area as it disintegration or dissolution in the saliva prior to disintegrates and dissolves rapidly swallowing for delivery into the gastrointestinal tract” [3].
    [Show full text]
  • Acrylamide Polymerization — a Practical Approach
    electrophoresis tech note 1156 Acrylamide Polymerization — A Practical Approach Paul Menter, Bio-Rad Laboratories, 2000 Alfred Nobel Drive, Polyacrylamide Gel Polymerization Hercules, CA 94547 USA AcrylamideBis Polyacrylamide Introduction The unparalleled resolution and flexibility possible with CH2 CH + CH2 CH CH2 CH CH2 CH CH2 CH polyacrylamide gel electrophoresis (PAGE) has led to its CO CO CO CO CO widespread use for the separation of proteins and nucleic NH2 NH NH2 NH2 NH acids. Gel porosity can be varied over a wide range to meet CH2 CH2 specific separation requirements. Electrophoresis gels and NH NH NH NH buffers can be chosen to provide separation on the basis of CO 2 2 CO CO C O charge, size, or a combination of charge and size. CH2 CH CH2 CH CH2 CH CH2 CH The key to mastering this powerful technique lies in the polymerization process itself. By understanding the important Purity of Gel-Forming Reagents parameters, and following a few simple guidelines, the novice Acrylamide can become proficient and the experienced user can optimize Gel-forming reagents include the monomers, acrylamide and bis, separations even further. as well as the initiators, usually ammonium persulfate and TEMED or, occasionally, riboflavin and TEMED. On a molar This bulletin takes a practical approach to the preparation of basis, acrylamide is by far the most abundant component in the polyacrylamide gels. Its purpose is to provide the information monomer solution. As a result, acrylamide may be the primary required to achieve reproducible, controllable polymerization. source of interfering contaminants (Dirksen and Chrambach For those users interested only in the “bare essentials,” the 1972).
    [Show full text]
  • Sucralfate Enemas
    Sucralfate Enemas Sucralfate enemas are used to treat inflammation of the rectum (the lower part of the large intestine leading to the anus); most commonly this is for radiation proctitis; bowel inflammation following radiotherapy. This treatment can help treat bleeding due to the inflammation, and can be continued for up to 24 weeks; you can stop when the bleeding stops. This fact sheet explains how you can administer the enema yourself, using a syringe and catheter. The hospital or community pharmacy can provide the Sucralfate enema, and you will need to ask your GP or practise nurse to supply the equipment you will need. Your practise nurse can help you practice preparing the enema, and could help you with administering it at home, if you find this difficult. 1. Using the syringe provided, draw up 10mls of the Sucralfate Suspension (2g) and then draw up 10mls of warm water and mix. Ensure that any excess air is expelled from the syringe. 2. Attach the catheter provided to the syringe tip and lubricate the end of the catheter with lubricating gel provided. 3. Lie on your left side with both knees bent. This position will help the flow of liquid in to the rectum and aid enema retention. 4. Position a towel underneath yourself to catch any leakage of fluid once the enema has been administered. 5. With a steady pressure, gently insert the catheter to a depth of approximately 10cm into the rectum. 6. Press down on the barrel of the syringe slowly, using a steady and even pressure, until the entire contents of the syringe have been administered.
    [Show full text]
  • The Reproductive System
    27 The Reproductive System PowerPoint® Lecture Presentations prepared by Steven Bassett Southeast Community College Lincoln, Nebraska © 2012 Pearson Education, Inc. Introduction • The reproductive system is designed to perpetuate the species • The male produces gametes called sperm cells • The female produces gametes called ova • The joining of a sperm cell and an ovum is fertilization • Fertilization results in the formation of a zygote © 2012 Pearson Education, Inc. Anatomy of the Male Reproductive System • Overview of the Male Reproductive System • Testis • Epididymis • Ductus deferens • Ejaculatory duct • Spongy urethra (penile urethra) • Seminal gland • Prostate gland • Bulbo-urethral gland © 2012 Pearson Education, Inc. Figure 27.1 The Male Reproductive System, Part I Pubic symphysis Ureter Urinary bladder Prostatic urethra Seminal gland Membranous urethra Rectum Corpus cavernosum Prostate gland Corpus spongiosum Spongy urethra Ejaculatory duct Ductus deferens Penis Bulbo-urethral gland Epididymis Anus Testis External urethral orifice Scrotum Sigmoid colon (cut) Rectum Internal urethral orifice Rectus abdominis Prostatic urethra Urinary bladder Prostate gland Pubic symphysis Bristle within ejaculatory duct Membranous urethra Penis Spongy urethra Spongy urethra within corpus spongiosum Bulbospongiosus muscle Corpus cavernosum Ductus deferens Epididymis Scrotum Testis © 2012 Pearson Education, Inc. Anatomy of the Male Reproductive System • The Testes • Testes hang inside a pouch called the scrotum, which is on the outside of the body
    [Show full text]
  • NAMS Practice Pearl
    NAMS Practice Pearl Restoring Vaginal Function in Postmenopausal Women With Genitourinary Syndrome of Menopause Released June 15, 2017 Risa Kagan, MD, FACOG, CCD, NCMP (University of California, San Francisco, and Sutter East Bay Medical Foundation, Berkeley, California) Eliza Rivera, PT, DPT, WCS (University of Florida Health, Jacksonville, Florida) Menopause practitioners are often asked to help postmenopausal women restore vaginal health and function. A common scenario is the postmenopausal woman who has been without a sexual partner for many years and is now about to resume or has already unsuccessfully attempted penetrative sexual activity. This Practice Pearl addresses the pathophysiology and effect of atrophic genital changes and offers advice on how vaginal health and comfortable sexual activity can be restored. The genitourinary syndrome of menopause (GSM) is the most common cause of dyspareunia in postmenopausal women.1,2 Before making this diagnosis, a careful examination to rule out other conditions, such as lichen sclerosis, should be performed. The genitourinary syndrome of menopause includes symptoms of vulvovaginal atrophy (VVA)—vulvar or vaginal dryness, discharge, itching, and dyspareunia—that occur from the loss of superficial epithelial cells and reduced collagen and elastin that lead to thinning of the tissue. Loss of vaginal rugae and elasticity result in a narrowing and shortening of the vagina as a direct result of the decline in estrogen and other sex steroids. The vaginal epithelium can become pale and friable, leading to tears and bleeding. The labia majora can lose subcutaneous fat, the introitus may narrow, loss of tissue from the labia minora and clitoris may occur, and the clitoral hood may fuse.
    [Show full text]
  • Colgate Blue Minty Gel Toothpaste This Industrial Safety Data Sheet Is Not Intended for Consumers and Does Not Address Consumer Use of the Product
    APJ Colgate Blue Minty Gel Toothpaste This industrial Safety Data Sheet is not intended for consumers and does not address consumer use of the product. For information regarding consumer applications of this product, refer to the product label. Version Revision Date: SDS Number: Date of last issue: - 1.0 23.11.2016 660000003786 Date of first issue: 23.11.2016 SECTION 1. PRODUCT AND COMPANY IDENTIFICATION Product name : Colgate Blue Minty Gel Toothpaste Product code : 200000015708 : B05408280003 Manufacturer or supplier's details Company : Colgate-Palmolive Co Colgate-Palmolive Central America Region Address : Colgate-Palmolive Pty Ltd., 345 George St, Sydney, New South Wales, Australia 2000. Telephone : Consumer affairs: - AU 1800 802 307 (Mon – Fri 9 - 5) Emergency telephone number : CHEMTREC Australia +(61)-290372994 Global-CHEMTREC- +1 703-741-5970 Telefax : +50250224239500 나.Recommended use of the chemical and restrictions on use Recommended use : A formulated dentifrice. SECTION 2. HAZARDS IDENTIFICATION GHS Classification Serious eye damage/eye irri- : Category 2A tation GHS label elements Hazard pictograms : Signal word : Warning Hazard statements : H319 Causes serious eye irritation. 1 / 11 APJ Colgate Blue Minty Gel Toothpaste This industrial Safety Data Sheet is not intended for consumers and does not address consumer use of the product. For information regarding consumer applications of this product, refer to the product label. Version Revision Date: SDS Number: Date of last issue: - 1.0 23.11.2016 660000003786 Date of first issue: 23.11.2016 Precautionary statements : Prevention: P264 Wash skin thoroughly after handling. P280 Wear eye protection/ face protection. Response: P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes.
    [Show full text]
  • NATIONAL INSTITUTE of SIDDHA Chennai
    NATIONAL INSTITUTE OF SIDDHA Chennai – 47 THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY, CHENNAI – 32 A STUDY ON PITHA PERUMPADU (DISSERTATION SUBJECT) For The Partial Fullfillment Of The Requirements to The Degree Of DOCTOR OF MEDICINE (SIDDHA) BRANCH I– MARUTHUVAM DEPARTMENT OCTOBER - 2013-2016 A CLINICAL EVALUVATION OF SIDDHA MEDICINE PERUMPADUKKU PITTU IN THE TREATMENT OF PITHA PERUMPADU (DYSFUNCTIONAL UTERINE BLEEDING) The dissertation Submitted by Dr.P.KAMALASOUNDARAM Under the Guidance of Prof. Dr. N.Periyasamy pandian, M.D(S) H.O.D i/c & Guide, Department of Maruthuvam, National Institute of Siddha, Dissertation submitted to THE TAMILNADU DR.MGR MEDICAL UNIVERSITY CHENNAI - 600032 In partial fulfillment of the requirements For the award of the degree of DOCTOR OF MEDICINE (SIDDHA) BRANCH - I - MARUTHUVAM 2013-2016 NATIONAL INSTITUTE OF SIDDHA, CHENNAI - 47 CONTENTS PAGE NO 4 1 INTRODUCTION 7 2 AIM AND OBJECTIVES 9 3 REVIEW OF LITERATURE A.SIDDHA ASPECTS 10 B. MODERN ASPECTS 35 63 4 MATERIALS AND METHODS 79 5 OBSERVATION AND RESULTS 116 6 DISCUSSION 122 7 SUMMARY 125 8 CONCLUSION 127 9 ANNEXURES 128 I PROFORMA 156 II PREPARATION OF TRAIL DRUG 159 III DRUG REVIEW 167 III BIO CHEMICAL ANALYSIS OF THE DRUG IV CERTIFICATES 175 180 10 BIBLIOGRAPHY 1 ACKNOWLEDGEMENT I feel immense awe and huge gratitude in my kindness of thanks to God almightly for making this dissertation have its present form. In all humality,I salute with great thanks to the Tamilnadu Dr.M.G.R Medical University and MINISTRY OF AYUSH , Govt. of India for granting permission to take this study.
    [Show full text]